.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Healthtrust
Cantor Fitzgerald
McKinsey
Chinese Patent Office
Dow
Daiichi Sankyo
Novartis
Covington

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202872

« Back to Dashboard
NDA 202872 describes LOTEMAX, which is a drug marketed by Bausch And Lomb, Pharmos, and Bausch And Lomb Inc, and is included in four NDAs. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the LOTEMAX profile page.

The generic ingredient in LOTEMAX is loteprednol etabonate. There are nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

Summary for 202872

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Ophthalmic Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202872

Medical Subject Heading (MeSH) Categories for 202872

Suppliers and Packaging for NDA: 202872

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LOTEMAX
loteprednol etabonate
GEL;OPHTHALMIC 202872 NDA Bausch & Lomb Incorporated 24208-503 24208-503-07 1 BOTTLE in 1 CARTON (24208-503-07) > 5 g in 1 BOTTLE
LOTEMAX
loteprednol etabonate
GEL;OPHTHALMIC 202872 NDA Bausch & Lomb Incorporated 24208-503 24208-503-48 1 BOTTLE in 1 CARTON (24208-503-48) > .5 g in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:GEL;OPHTHALMICStrength0.5%
Approval Date:Sep 28, 2012TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jan 29, 2017Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 202872

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb Inc
LOTEMAX
loteprednol etabonate
GEL;OPHTHALMIC202872-001Sep 28, 2012► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Cantor Fitzgerald
Merck
Chinese Patent Office
Express Scripts
McKinsey
Fish and Richardson
US Department of Justice
Federal Trade Commission
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot